WhatsApp
backNews Article

Gland Pharma Delivers 23% Revenue Growth and 58% PAT Increase in Q2 FY27

Company launches four new US products and records 50% rise in adjusted EBITDA for the quarter ended September 2026

Gland Pharma posted a 23% year-on-year rise in revenue to ₹18,336 million and a 58% increase in PAT to ₹2,908 million for Q2 FY27. Gross profit margin remained steady at 63%, while EBITDA margin improved to 26%. The company also launched four new products in the US and filed eleven ANDAs during the quarter, further expanding its product portfolio and pipeline.

06 Nov 2026|GLAND+0.35%
Gland Pharma LimitedBSE:543245NSE:GLANDInvestor Presentation

Gland Pharma Limited

Investor Presentation

Gland Pharma Limited reported strong financial performance for the quarter ended September 30, 2026, with revenues increasing 23% year-over-year to ₹18,336 million and profit after tax rising 58% to ₹2,908 million. The company also bolstered its product lineup with four new launches in the US and significant progress in regulatory approvals.

For Q2 FY27, consolidated revenue from operations was ₹18,336 million, up 23% from ₹14,869 million in Q2 FY26. Gross profit stood at ₹11,638 million with a margin of 63%, consistent with the prior year. EBITDA expanded 53% to ₹4,804 million, while the EBITDA margin improved to 26% compared to 21% in Q2 FY26. Adjusted EBITDA, accounting for stock compensation and GST provisions, rose 50% to ₹5,030 million.

Profit before tax (PBT) increased 52% year-over-year to ₹4,309 million, with a PBT margin of 24%. Net profit or PAT for the quarter was ₹2,908 million, marking a 58% gain over the prior year period, and the PAT margin reached 16%.

The company operates two main business segments: Contract Development and Manufacturing Organization (CDMO) and Critical Injectables. CDMO revenue for the quarter was ₹8,227 million, a 31% increase, while Critical Injectables posted ₹10,109 million, up 18%. This reflects ongoing growth supported by new launches and increased demand.

Research and development expenses totaled ₹1,077 million or 6% of consolidated revenue, focused primarily on complex product development and regulatory filings. In Q2 FY27, Gland Pharma launched four new injectable molecules in the US market: Sugammadex, Erythromycin, Fluorouracil, and Atropine sulfate.

During the quarter, the company filed eleven Abbreviated New Drug Applications (ANDAs) and secured approvals for ten, bringing the total ANDA filings to 399 with 350 approved and 49 pending. The in-house complex injectables portfolio continues to expand, with six products launched and three additional pending approval.

Highlights

  • Q2 FY27 revenue increased 23% year-on-year to ₹18,336 million.
  • Adjusted EBITDA rose 50% to ₹5,030 million with a margin of 27%.
  • Profit after tax grew 58% to ₹2,908 million, improving PAT margin to 16%.
  • CDMO segment revenue increased 31%, Critical Injectables up 18%.
  • Four new injectable products launched in the US market during Q2 FY27.
  • Filed eleven ANDAs and received ten approvals in the quarter, totaling 399 filings to date.

Key Data Snapshot

Revenue from Operations Q2 FY27₹18,336 million
Revenue Growth YoY Q2 FY27 vs Q2 FY2623%
Profit After Tax (PAT) Q2 FY27₹2,908 million
PAT Growth YoY Q2 FY27 vs Q2 FY2658%
Gross Profit Margin Q2 FY2763%
EBITDA Q2 FY27₹4,804 million
EBITDA Margin Q2 FY2726%
Adjusted EBITDA Q2 FY27₹5,030 million
Adjusted EBITDA Margin Q2 FY2727%
PBT Q2 FY27₹4,309 million
PBT Margin Q2 FY2724%
R&D Expenses Q2 FY27₹1,077 million
R&D Expense as % of Revenue Q2 FY276%
CDMO Revenue Q2 FY27₹8,227 million (31% YoY growth)

What happened

  • Gland Pharma reported a 23% year-over-year rise in consolidated revenue to ₹18,336 million in Q2 FY27.
  • Profit after tax increased 58% to ₹2,908 million for the quarter ended September 2026.
  • EBITDA expanded 53% to ₹4,804 million with margin improving to 26%.
  • The company launched four new injectable products in the US market during the quarter.
  • Eleven ANDAs were filed and ten received approval, advancing the company's regulatory portfolio.

Key details

  • Gross profit margin remained stable at 63% for Q2 FY27.
  • Adjusted EBITDA, including stock option expenses and GST provisions, rose 50% to ₹5,030 million, with a 27% margin.
  • The CDMO segment revenue grew 31% to ₹8,227 million, supported by new products and higher volumes.
  • Critical Injectables segment revenue increased 18% to ₹10,109 million.
  • R&D spending totaled ₹1,077 million, representing 6% of consolidated revenues, focusing on complex product development.

Business impact

  • The launches of Sugammadex, Erythromycin, Fluorouracil, and Atropine sulfate are expected to contribute to future growth in the US market.
  • The company’s 399 cumulative ANDA filings include 350 approvals and 49 pending, underpinning a strong regulatory pipeline.
  • Complex injectable portfolio remains a key growth pillar with six products launched and three more awaiting approval.
  • Gland Pharma's balanced revenue mix between CDMO and Critical Injectables continues to support steady overall growth.

Background and context

  • The investor presentation was dated 6th November 2026, reporting Q2 FY27 results ending September 2026.
  • Revenue growth reflects increased demand and new product introductions amid stable gross profit margins.
  • Forward-looking statements within the presentation caution about risks including economic conditions, regulatory changes, and competition.
  • The company operates primarily in contract development/manufacturing and critical injectable medicines sectors.

More News on Investor Presentation

View all

Latest corporate announcements and market updates in Investor Presentation.

View all news
Gland Pharma Delivers 23% Revenue Growth and 58% PAT | Stockk News